Sequencing Agents to Treat Castration-Resistant Prostate Cancer

October 25, 2013
Special Reports, Genitourinary Cancers, Volume 1, Issue 1

Leonard G. Gomella, MD, FACS, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer.

Leonard G. Gomella, MD, FACS, Chair and Professor, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer (CRPC).

Read more about immunotherapy for the treatment of CRPC > >